NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Atavistik Bio

Atavistik Bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://atavistikbio.com/

Last Round

Series B

Mar 5, 2026

Total Funding Raised

$460M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Atavistik Bio is a biopharmaceutical company that discovers and develops precision allosteric small molecule therapeutics for metabolic diseases and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

drug discoveryallosteric inhibitorssmall-molecule therapeuticsprecision medicineAI drug discoveryatavistik metabolite-proprietary screeningAMPScomputational biologyundruggable targetsbiotechin silico drug designmetabolic diseaseoncologystructure-based designpharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Atavistik Bio Comparables

Compare Atavistik Bio with similar companies based on industry and business-model similarity.

Atavistik Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alterome Therapeutics
88%
HotSpot Therapeutics
86%
Frontier Medicines
83%

Atavistik Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 5, 2026
Series BDec 18, 2025
Series A ExtensionDec 19, 2023
Series AAug 24, 2021

Key People

Founding team and executive leadership

Bryan Stuart

Chief Executive Officer

Executive Team

Aninda Katragadda

Chief Financial Officer

Executive Team

Atavistik Bio Investors

Notable investors and investment history

Atavistik Bio investors
InvestorRounds
The Column GroupSeries B, Series A, Series A Extension
RA Capital ManagementSeries B
Lux CapitalSeries A, Series B, Series A Extension
The Chernin GroupSeries A, Series A Extension
Nextech InvestSeries A, Series B, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 16, 2026

    Agent ZE74-0282 is currently in Phase I clinical trials.

  • Mar 16, 2026

    Advancing an allosteric JAK2 V617F inhibitor toward clinical proof of concept.

Atavistik Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Atavistik Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Atavistik Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range40
Year Founded2021
Last FundingMar 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.